MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs DSO Ratio 2011-2026 | PRPH
Annual DSO Ratio ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 | 94.3 | 0.0793 | 252 | 217 | 183 | 100 | 70.9 | 96.5 | 77.6 | 88.1 | 67.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 252 | 0.0793 | 113 |
Quarterly DSO Ratio ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 K | 1.47 K | 1.28 K | - | 2.08 K | - | - | - | 421 | 264 | 177 | - | 140 | 115 | 71.4 | - | 83.2 | 105 | 52.2 | - | 75 | 79.5 | 125 | - | 66.3 | 111 | 98 | - | 111 | 85 | 65.8 | - | 58.4 | 93.2 | 35.7 | - | 376 | 516 | 439 | 44.7 | 83.1 | 167 | 76.6 | 59.4 | 104 | 296 | 82.5 | 50.5 | 81.6 | 250 | 64.9 | 54.4 | 91.2 | 261 | 65.4 | 39.4 | 57.8 | 168 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 K | 35.7 | 253 |
DSO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
16.5 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
100 | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
49.9 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
375 | $ 3.12 | 0.97 % | $ 43.9 M | USA |
 |
Cronos Group
CRON
|
203 | $ 2.57 | -0.39 % | $ 1.35 B |  Canada |
 |
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
78.9 | $ 5.72 | 2.14 % | $ 2.09 B | Canada |
 |
Harrow Health
HROW
|
152 | $ 37.1 | 3.26 % | $ 1.36 B | USA |
 |
Aurora Cannabis
ACB
|
99.8 | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
62.7 | $ 1.08 | 2.86 % | $ 116 M | Canada |
 |
OrganiGram Holdings
OGI
|
93 | $ 1.42 | 1.43 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
32.2 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
62.9 | $ 4.33 | 1.41 % | $ 279 M | USA |
 |
Emergent BioSolutions
EBS
|
60.9 | $ 8.24 | 3.52 % | $ 422 M | USA |
 |
Tilray
TLRY
|
52.8 | $ 6.72 | 2.28 % | $ 4.15 B | Canada |
 |
Organogenesis Holdings
ORGO
|
72.6 | $ 2.38 | - | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
50.3 | $ 24.06 | 1.13 % | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
91.5 | $ 2.38 | - | $ 321 M | USA |
 |
Viatris
VTRS
|
78.8 | $ 13.83 | 2.67 % | $ 16.6 B | USA |
 |
cbdMD
YCBD
|
11.3 | $ 0.75 | 9.54 % | $ 3.23 M | USA |
 |
Assertio Holdings
ASRT
|
268 | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
16.1 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
62.7 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
138 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 1.01 | 1.0 % | $ 50.4 M | USA |
 |
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
65.5 | $ 2.35 | 3.07 % | $ 2.92 M | USA |
 |
Zomedica Corp.
ZOM
|
31 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
43.3 | $ 0.94 | 3.31 % | $ 33.8 M | USA |
 |
China Pharma Holdings
CPHI
|
20.9 | $ 0.65 | 0.6 % | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
2.3 K | $ 2.05 | -0.97 % | $ 23.7 M | USA |